A Phase 2 Study of Neratinib with or without Fulvestrant in HER2-Positive ER-Positive Metastatic Breast Cancer

Recruiting
18 years - 100 years
Female
Phase N/A
1 Location

Brief description of study

The purpose of this research study is to determine how well neratinib, by itself or together with Fulvestrant, works in treating breast cancer that has spread to other parts of the body. We will also be looking at the side effects associated with this combination of drugs.

Detailed description of study

This is a Phase II study to determine how well neratinib, alone or together with Fulvestrant (FDA approved), works in treating breast cancer that has spread to other parts of the body.
Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: HER2,metastatic breast cancer,metastatic,breast cancer,cancer,oncology
  • Age: 18 years - 100 years
  • Gender: Female

Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Females 18 years or older
  • Inoperable locally advanced or metastatic ER+ breast cancer.

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 04 Aug 2024. Study ID: 1803730353 (17-318)

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team